Used primarily in cancer research, Tenovin-6 activates the p53 pathway by inhibiting MDM2, a protein that degrades p53. This stabilization of p53 promotes apoptosis in tumor cells, making it a valuable tool in studies of oncology and drug development. It shows activity against various cancer cell lines, including those resistant to conventional therapies. Additionally, Tenovin-6 has been investigated for its potential to enhance the effectiveness of other anticancer agents through synergistic effects. Its ability to cross cell membranes efficiently supports its use in cellular and in vivo models.